

Piśmiennictwo

1. Arendrup M.C. et al: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infection. *Clinical Microbiology and Infection*, 2014, 20 (Suppl. 3)
<https://doi.org/10.1111/1469-0691.12360>
2. Aspergillus and Aspergillosis website: <https://www.aspergillus.org.uk/>
- Boutin C.A.: Update on therapeutic approaches for invasive fungal infections in adults. *Ther. Adv. Infect. Dis.* 2024, 11:20499361231224980.
3. Buchta et al.: *Saprochaete clavata* invasive infection – a new threat to hematological-oncological patients. *Frontiers in Microbiology* 2019, 10:2196 doi: 10.3389/fmicb.2019.021963
4. Chowdhary A. et al.: A multicentre study of antifungal susceptibility patterns among 350 *Candida auris* isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. *Journal of Antimicrobial Chemotherapy*, 2018, 73.
5. Cornely O.A. et al.: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clinical Microbiology and Infection*, 2014, 20 (Suppl. 3)
<https://doi.org/10.1111/1469-0691.12371>
6. Cornely O. et al.: Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *The Lancet Infectious Diseases*, November 2019, DOI: 10.1016/S1473-3099(19)30312-3.
7. Cortegiani A. et al.: Epidemiology, clinical characteristics, resistance, and treatment of infections by *Candida auris*. *Journal of Intensive Care*, 2018, 6:69, <https://doi.org/10.1186/s40560-018-0342-4>
8. Desnos-Ollivier M.: Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). *Clinical Microbiology and Infection*, 2019; 25:634.e1e634.e4, DOI: <https://doi.org/10.1016/j.cmi.2019.02.007>
9. Dromer F., Bretagne S., Lortholary O.: Rapport annuel d'activité 2019. Centre de National de Référence Mycoses Invasives et Antifongiques Année d'exercice 2018.
- EUCAST Breakpoint tables for interpretation of MICs for antifungal agents. Version 10.0, valid from 2020-02-04.
10. European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs for antifungal agents, Version 10.0, valid from 2020-02-04.
11. Falci D.R., Pasqualotto A.C.: Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. *Infection and Drug Resistance*, 2013, 22 (Suppl. 6).
12. FDA Briefing Document. Anti-Infective Drugs Advisory Committee Meeting (2015). Invasive Aspergillosis and Invasive Mucormycosis. NDA 207-500: Cresemba® (Isavuconazonium) for Injection; NDA 207-501 Cresemba® (Isavuconazonium) Capsules.
- Feuss A. et al.: The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies. *J. Fungi* 2024, 10, 345.

13. Frederic Tissot et al.: ECIL-6 Guidelines For The Treatment Of Invasive Candidiasis, Aspergillosis and Mucormycosis in Leukemia and Hematopoietic Stem Cell Transplant Patients. *Haematologica*, 2017, 102 Doi:10.3324/haematol.2016.152900
14. Francisco E.C. et al.: Species distribution and antifungal susceptibility of 358 *Trichosporon* clinical isolates collected in 24 medical centres. *Clinical Microbiology and Infections*, 2019, 25 (Suppl. 7) <https://doi.org/10.1016/j.cmi.2019.03.026>
15. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. ISBN 978-92-4-155027-7, World Health Organisation, 2018.
16. International Commission of Penicillium and Aspergillus. A Commission of the International Union of Microbiological Societies <https://www.aspergilluspenicillium.org/>
17. Index Fungorum <https://www.indexfungorum.org/>
- Kriegel L. et al.: New treatment options for critically important WHO fungal priority pathogens. *Clin. Microbiol. Infect.* 2024, S1198-743X(24)00118-6.
- Mesquida A. et al.: In vitro activity of ibrexafungerp against *Candida* species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. *Clin. Microbiol. Infect.* 2022, 28:140.e1e140.e4.
18. Mycobank, central repository of species information. <https://www.mycobank.org/>
19. National Mycology Reference Centre: <http://www.mycology.adelaide.edu.au/> <https://www.adelaide.edu.au/mycology/>
20. Pajol et al.: Flucytosine resistance is restricted to a single genetic clade of *Candida albicans*. *Antimicrobial Agents Chemotherapy* 2004, 48(1), 262.
- Pfaller M.A. et al.: Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020). *Antimicrob. Agents Chemother.* 2022, 66(11):e0102822.
- Pfaller M.A. et al.: In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against *Aspergillus* spp. by CLSI and EUCAST Broth Microdilution Methods. *Antimicrob. Agents Chemother.* 2013, 57: 1065-1068.
21. Pfaller M.A. et al.: In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds. *Journal of Clinical Microbiology* (2013), 51 (Suppl. 8).
22. Pfaller M.A. et al.: Twenty Years of the SENTRY Antifungal Surveillance Program: Results for *Candida* Species From 1997-2016. 2019, *Open Forum Infectious Diseases*, 2nd ed., 6, S79-S94.
23. Tortorano A.M. et al.: ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: *Fusarium* spp., *Scedosporium* spp. and others. *Clinical Microbiology and Infection*, 2014, 20 (Suppl. 3) <https://doi.org/10.1111/1469-0691.12465>
24. Westerdijk Fungal Biodiversity Institute (former CBS). <http://www.westerdijkinstitute.nl/> <https://wi.knaw.nl/>

